目的 探讨苏合香丸联合阿加曲班治疗急性脑梗死患者的临床疗效。方法 选择2019年12月—2021年9月河南省直属机关第一门诊部收治的82例急性脑梗死患者，随机分为对照组和治疗组，每组各41例。对照组静脉滴注阿加曲班注射液，10 mg/次，2次/d。治疗组在对照组的基础上口服苏合香丸，1丸/次，2次/d。两组患者连续治疗10 d。观察两组患者临床疗效，比较治疗前后两组患者症状好转时间，血清因子白细胞介素-6（IL-6）、同型半胱氨酸（Hcy）、肿瘤坏死因子-α（TNF-α）、超敏C反应蛋白（CRP）水平及神经功缺损程度（NIHSS）评分和不良反应发生率。结果 治疗后，治疗组临床有效率明显高于对照组（97.56%vs 78.05%，P<0.05）。治疗后，治疗组临床出现的肢体感觉减退、自理能力下降、中枢性面瘫、感觉性失语等症状好转时间均早于对照组（P<0.05）。治疗后，两组患者血清因子IL-6、Hcy、TNF-α和CRP水平，及NIHSS评分均明显下降（P<0.05），且治疗组明显低于对照组（P<0.05）。治疗组不良反应发生率为7.32%，明显低于对照组的17.07%（P<0.05）。结论 苏合香丸联合阿加曲班治疗急性脑梗死，能有效改善急性脑梗死症状，对脑神经损伤程度好转明显，并有效降低炎症反应。

Objective To explore the clinical effect of Suhexiang Pills combined with argatroban in treatment of acute ischemic stroke. Methods Patients (82 cases) with acute ischemic stroke in the First Outpatient Department of Organs Directly under Henan Province from December 2019 to September 2021 were randomly divided into control and treatment group, and each group had 41 cases. Patients in the control group were iv administered with Argatroban Injection, 10 mg/time, twice daily. Patients in the treatment group were po administered with Suhexiang Pills on the basis of the control group, 1 pill/time, twice daily. Patients in two groups were treated for 10 d. After treatment, the clinical evaluation was evaluated, the improvement time of symptoms, serum factors levels IL-6, Hcy, TNF-α and CRP, NIHSS scores, incidence of adverse reactions in two groups before and after treatment were compared. Results After treatment, the clinical effective rate of the treatment group was significantly higher than that of the control group (97.56% vs 78.05%, P < 0.05). After treatment, the improvement time of clinical symptoms such as decreased limb sensation, decreased self-care ability, central facial paralysis and sensory aphasia in the treatment group was earlier than that in the control group (P < 0.05). After treatment, the levels of serum factors IL-6, Hcy, TNF-α and CRP and NIHSS scores in two groups were significantly decreased (P < 0.05), and which in the treatment group were significantly lower than those in the control group (P < 0.05). The incidence of adverse reactions in the treatment group was 7.32%, and which was lower than 17.07% in the control group (P < 0.05). Conclusion The combined treatment of Suhexiang Pills and Argatroban Injection can effectively improve the acute symptoms of ischemic stroke, significantly improve the degree of brain nerve damage, and effectively reduce the inflammatory response.

R971